Get started
Author

I-SPY Investigators

Observed names: . I-SPY Investigators, I-SPY 2 Investigators, I-SPY 2 TRIAL Investigators, I-SPY 2 TRIAL investigators, I-SPY Trial Investigators and Patient Advocates., I-SPY investigators, I-SPY2 Investigators, I-SPY2 investigators, Investigators I-SPY
OpenAlex ID: A5009944734
Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes
2023 · Katharine Yu, Amrita Basu, et al. · Frontiers in Oncology · 6
Abstract 2612: BluePrint Luminal subtype predicts non-response to HER2-targeted therapies in HR+/HER2+ I-SPY 2 breast cancer patients
2018 · Pei Rong Evelyn Lee, Zelos Zhu, et al. · Cancer Research · 4
Abstract 2611: Evaluation of ANG/TIE/hypoxia pathway genes and signatures as predictors of response to trebananib (AMG 386) in the neoadjuvant I-SPY 2 TRIAL for Stage II-III high-risk breast cancer
2018 · Denise M. Wolf, Christina Yau, et al. · Cancer Research · 2
Metadata record for the manuscript: The Quality of Life Index (QoLI): A Pilot Study Integrating Treatment Efficacy and Quality of Life in Oncology Clinical Trials
2020 · Basu, Amrita, Philip, Errol J., et al. · Figshare · 1
DNA repair deficiency biomarkers and identification of ER-positive breast cancer patients who may benefit from veliparib/carboplatin: Results from the I-SPY 2 trial.
2015 · Laura van’t Veer, Laura Esserman, et al. · Journal of Clinical Oncology · 1
Abstract 2994: Integrative pathway analysis of I-SPY2 HER2+ breast cancers reveals drug-repurposing opportunities
2026 · Kingsley V. Chow, Tam Binh Bui, et al. · Cancer Research
Abstract PS3-11-10: Neoadjuvant HSP90 inhibition with ganetespib significantly improves distant relapse-free survival in I-SPY2 patients with HER2-negative breast cancer with low expression of immune genes and no DNA repair deficiency
2026 · T. B. V. Bui, D. M. Wolf, et al. · Clinical Cancer Research
Abstract PD6-09: Quantifying the Contribution of Doxorubicin and Cyclophosphamide (AC) to Pathologic Response Following Neoadjuvant Taxane Therapy: Analysis of the I-SPY2 TRIAL
2026 · D. Yee, C. Yau, et al. · Clinical Cancer Research
Abstract RF1-04: Early Adverse Symptoms Predict Response to Treatment Among Patients in the I-SPY Trial
2026 · A. Basu, S. Umashankar, et al. · Clinical Cancer Research
Abstract PS1-01-05: Pneumonitis but not other immune related adverse events (irAEs) associate with pre-treatment immune signatures in early-stage breast cancer patients receiving neoadjuvant immunotherapy (IO): results from 5 IO arms in I-SPY2
2026 · D. M. Wolf, H. Rugo, et al. · Clinical Cancer Research
Abstract PD5-04: PD5-04 Characterizing the HER2-/Immune-/DNA repair (DRD-) response predictive breast cancer subtype: the hunt for new protein targets in a high-needs population with low response to all I-SPY2 agents
2023 · Denise M. Wolf, Christina Yau, et al. · Cancer Research
I-SPY 2 low risk registry: An I-SPY 2 trial sub-study for women with clinically advanced, ER+, HER2- breast cancer and molecular good-prognosis gene signature.
2015 · Tufia C. Haddad, Mamta D. Shah, et al. · Journal of Clinical Oncology
Abstract PD07-09: Hypoxia (VEGF-S) Signature and CRYAB Predict Response to Neoadjuvant Anthracycline/Taxane Containing Chemotherapy within Triple Negative and Unselected Breast Tumors
2010 · MCU Cheang, JS Parker, et al. · Cancer Research
From the Lab to the Clinic: Gene-Expression Profiles That Are Associated with Mek-Inhibitor Sensitivity In Vitro Are Coordinately Co-Expressed in Breast Cancer Biopsy Samples from the I-SPY Trial (CALGB 150007/150012, ACRIN 6657).
2009 · D. Wolf, D. Das, et al. · Cancer Research
Works count: 14
Citation count: 14
H-index: 2
I10-index:
Year
Topic
Type